Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 7/20 | 0.67 |
| ▸ | CA2 | P00918 | 7/20 | 0.67 |
| ▸ | CA12 | O43570 | 6/20 | 0.67 |
| ▸ | CA7 | P43166 | 6/20 | 0.67 |
| ▸ | CA9 | Q16790 | 6/20 | 0.67 |
| ▸ | CA14 | Q9ULX7 | 6/20 | 0.67 |
| ▸ | XDH | P47989 | 2/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.59 |
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | HPGD | P15428 | 3/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.59 |
| ▸ | TP53 | P04637 | 2/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.59 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29826125 | 1.00 | CA1 (0.67) | CA1CA2CA12CA7CA9 | |
| SCHEMBL403210 | 0.89 | CA12 (0.71) | CA1CA2CA12CA7CA9 | |
| SCHEMBL15660162 | 0.86 | CA12 (0.62) | CA1CA2CA12CA7CA9 | |
| SCHEMBL330670 | 0.85 | CA12 (0.65) | CA1CA2CA12CA7CA9 | |
| SCHEMBL136284 | 0.85 | CA1 (0.67) | CA1CA2CA12CA7CA9 | |
| SCHEMBL15543469 | 0.85 | TDP1 (0.52) | CA1CA2CA12CA7CA9 | |
| SCHEMBL5917807 | 0.85 | CA12 (0.67) | CA1CA2CA12CA7CA9 | |
| SCHEMBL31258831 | 0.85 | CA12 (0.65) | CA1CA2CA12CA7CA9 | |
| SCHEMBL552572 | 0.84 | CA12 (0.65) | CA1CA2CA12CA7CA9 | |
| SCHEMBL2459449 | 0.83 | KDM4E (0.62) | CA1CA2CA12CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163038-A1 | CBL-B MODULATORS AND USES THEREOF | NIMBUS CLIO, INC. | 2025-05-22 | — | — | US | disclosed |
| CN-115427035-B | ENL/AF9 YEATS inhibitors | 洛克菲勒大学 | 2025-04-22 | — | — | CN | disclosed |
| CN-118638089-B | Preparation method for synthesizing flavonoid compound based on carbon dioxide | 湖南工程学院 | 2024-11-12 | — | — | CN | disclosed |
| CN-118638089-A | Preparation method for synthesizing flavonoid compound based on carbon dioxide | 湖南工程学院 | 2024-09-13 | — | — | CN | disclosed |
| US-20240166617-A1 | PHOSPHOINOSITIDE 3 KINASE BETA INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | GEODE THERAPEUTICS INC (US) | 2024-05-23 | — | — | US | disclosed |
| US-20240158390-A1 | OTHER HETEROAROMATIC COMPOUNDS HAVING ACTIVITY AGAINST RSV | JANSSEN SCIENCES IRELAND UNLMITED COMPANY (IE) | 2024-05-16 | — | — | US | disclosed |
| EP-4359381-A1 | CBL-B MODULATORS AND USES THEREOF | Nimbus Clio, Inc. (US) | 2024-05-01 | — | — | EP | disclosed |
| CN-117858865-A | CBL-B modulators and uses thereof | 林伯士克莱奥公司 | 2024-04-09 | — | — | CN | disclosed |
| CN-117615763-A | Phosphoinositide 3 kinase beta inhibitor, composition and preparation method thereof | 健道生物医药有限公司 | 2024-02-27 | — | — | CN | disclosed |
| EP-4284375-A1 | PHOSPHOINOSITIDE 3 KINASE BETA INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | Geode Therapeutics Inc. (US) | 2023-12-06 | — | — | EP | disclosed |
| US-4183945-A | ANTIANAPHYLACTIC AGENTS | CARLO ERBA S.P.A. (IT) | 1980-01-15 | — | — | US | disclosed |
| US-4177276-A | ANIT-ALLERGY ACTIVITY | FARMITALIA CARLO ERBA, S.P.A. (IT) | 1979-12-04 | — | — | US | disclosed |
| US-4177286-A | ANTIALLERGENS | FARMITALIA CARLO ERBA, S.P.A. (IT) | 1979-12-04 | — | — | US | disclosed |
| US-4157334-A | ANTIALLERGENS, SPASMOLYTIC | CARLO ERBA S. P. A. (IT) | 1979-06-05 | — | — | US | disclosed |
| US-4152449-A | ANTIALLERGENS | CARLO ERBA S. P. A. (IT) | 1979-05-01 | — | — | US | disclosed |
| US-4148900-A | ANTIALLERGIC | CARLO ERBA S.P.A. (IT) | 1979-04-10 | — | — | US | disclosed |
| US-4143145-A | ANTIALLERGENS | CARLO ERBA S. P. A. (IT) | 1979-03-06 | — | — | US | disclosed |
| US-4115567-A | TREATMENT OF ALLERGIES | CARLO ERBA S. P. A. (IT) | 1978-09-19 | — | — | US | disclosed |
| US-4083953-A | ANTIALLERGENS | CARLO ERBA, S.P.A. (IT) | 1978-04-11 | — | — | US | disclosed |
| US-4065467-A | ANTIALLERGENS, ANTIULCER AGENTS, TREATMENT OF RESPIRATORY SYSTEM AND PULMONARY DISORDERS | CARLO ERBA, S. P. A. (IT) | 1977-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163038-A1 | CBL-B MODULATORS AND USES THEREOF | CBLB, CBL, CBLC | CA1 4855/4885CA2 4707/4885CA12 4823/4885 |
| US-20240158390-A1 | OTHER HETEROAROMATIC COMPOUNDS HAVING ACTIVITY AGAINST RSV | MAVS, ZC3HAV1, RNASEH1 | CA1 4820/4885CA2 3533/4885CA12 3925/4885 |
| US-20240166617-A1 | PHOSPHOINOSITIDE 3 KINASE BETA INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | PIK3CA, PIK3CB, PI4KA | CA1 2855/4885CA2 2216/4885CA12 4143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.